Patients with HER2-overexpressed metastatic NSCLC (DESTINY-Lung01) received either 6.4 mg/kg (cohort 1) or 5.4 mg/kg (cohort 1A). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.